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Abstract
Background: High blood pressure (BP) is the leading attributable risk for cardiovascular disease (CVD). In rural
South Asia, hypertension continues to be a significant public health issue with sub-optimal BP control rates. The
goal of the trial is to compare a multicomponent intervention (MCI) to usual care to evaluate the effectiveness and
cost-effectiveness of the MCI for lowering BP among adults with hypertension in rural communities in Bangladesh,
Pakistan and Sri Lanka.
Methods/design: This study is a stratified, cluster randomized controlled trial with a qualitative component for
evaluation of processes and stakeholder feedback. The MCI has five components: (1) home health education by
government community health workers (CHWs), (2) BP monitoring and stepped-up referral to a trained general
practitioner using a checklist, (3) training public and private providers in management of hypertension and using a
checklist, (4) designating hypertension triage counter and hypertension care coordinators in government clinics and
(5) a financing model to compensate for additional health services and provide subsidies to low income individuals
with poorly controlled hypertension. Usual care will comprise existing services in the community without any
additional training.
The trial will be conducted on 2550 individuals aged ≥40 years with hypertension (with systolic BP ≥140 mm Hg
or diastolic BP ≥90 mm Hg, based on the mean of the last two of three measurements from two separate days,
or on antihypertensive therapy) in 30 rural communities in Bangladesh, Pakistan and Sri Lanka. The primary
outcome is change in systolic BP from baseline to follow-up at 24 months post-randomization. The incremental
cost of MCI per CVD disability-adjusted life years averted will be computed.
Stakeholders including policy makers, provincial- and district-level coordinators of relevant programmes,
physicians, CHWs, key community leaders, hypertensive individuals and family members in the identified
clusters will be interviewed.
(Continued on next page)
* Correspondence: tazeen.jafar@duke-nus.edu.sg
1Program in Health Services & Systems Research, Duke-NUS Medical School,
8 College Road, Singapore 169857, Singapore
2Duke Global Health Institute, Duke University, Durham, NC, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Jafar et al. Trials  (2017) 18:272 
DOI 10.1186/s13063-017-2018-0
(Continued from previous page)
Discussion: The study will provide evidence of the effectiveness and cost-effectiveness of MCI strategies for
BP control compared to usual care in the rural public health infrastructure in South Asian countries. If shown
to be successful, MCI may be a long-term sustainable strategy for tackling the rising rates of CVD in low
resourced countries.
Trial registration: ClinicalTrials.gov, NCT02657746. Registered on 14 January 2016.
Keywords: Hypertension, Lifestyle, Home health, Behaviour change, Cardiovascular risk, Public health,
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Background
Cardiovascular disease (CVD) is a leading cause of mor-
tality globally, accounting for 30% of deaths, even in
low- and middle-income countries [1, 2]. In South Asia,
high rates of CVD are observed at a younger age than in
other countries, causing a greater loss of productive life
years with severe economic consequences. Population
blood pressure (BP) levels and rates of hypertension
continue to rise in South Asia [3].
We have previously demonstrated the benefit of a
model of care (COBRA: Control of Blood Pressure
and Risk Attenuation), which combines family-based
home health education (HHE) with trained private
general practitioners (GPs), on lowering BP in urban
Pakistan [4]. The combination of two interventions
was superior than single or no intervention (usual
care). However, the strategies were not evaluated in
rural areas of Pakistan or any other South Asian
country. Moreover, the urban model did not use the
public health infrastructure for care delivery. Most of
South Asia is still rural, where the prevalence of
hypertension is high (one in four adults suffers from
hypertension, and most cases are poorly controlled),
and cardiovascular case fatality rates have been shown
to be higher than in urban areas. Thus, evidence-
based interventions applicable to rural South Asia are
urgently needed.
Recently, we reported findings from a feasibility
study to modify the COBRA model of care as a multi-
component intervention (MCI) for optimal delivery
using the public health infrastructure in rural regions
in Bangladesh, Pakistan and Sri Lanka (the COBRA-
BPS feasibility study) [5]. The feasibility study also
explored system-level barriers and facilitators of imple-
mentation of the MCI. Common standardized proto-
cols and manuals for training community health
workers (CHWs) and GPs in all three countries were
developed. The feedback and suggestions from the
stakeholders have already been incorporated in the
full-scale trial protocol to be evaluated for fidelity, ef-
fectiveness and cost-effectiveness of the MCI model
of care that we refined based on the COBRA-BPS
feasibility study. The current protocol paper describes
the full-scale COBRA-BPS trial in detail.
Methods/design
We will evaluate the effectiveness of the MCI model of
care compared to usual care in lowering systolic blood
pressure (SBP) levels over 2 years among 2550 individ-
uals aged 40 years or older with hypertension (those
with SBP ≥140 mm Hg or diastolic blood pressure
(DBP) ≥90 mm Hg based on the mean of the last two
of three measurements from two separate days, or on
antihypertensive therapy) in 30 rural communities in
Bangladesh, Pakistan and Sri Lanka.
The MCI has five components: (1) HHE by govern-
ment CHWs, (2) BP monitoring and stepped-up refer-
ral to a trained GP using a checklist, (3) training public
and private providers in management of hypertension
and using a checklist, (4) designating hypertension tri-
age counter and hypertension care coordinators in
government clinics and (5) a financing model to com-
pensate for additional health services and provide sub-
sidies to low income individuals with poorly controlled
hypertension.
Main and additional aims of the trial
The main aims of the trial are:
1. To evaluate whether the MCI (described with
components 1–5 above) is better than usual
care in lowering BP among adults with
hypertension in rural communities
2. To quantify the incremental cost-effectiveness
of the MCI approach in terms of cost per projected
cardiovascular disease disability-adjusted life years
(CVD DALYs) averted from the societal,
government and participant perspectives.
Additional aims are:
3. To determine whether MCI improves medication
adherence and lowers body mass index (BMI),
dietary sodium, smoking rates, lipid levels, glucose
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levels and INTERHEART CVD risk score relative to
usual care [6]
4. To determine whether MCI will lead to a greater
reduction in 24-h ambulatory blood pressure among
individuals with poorly controlled hypertension
(defined as those with persistently elevated SBP
>140 mm Hg or DBP >90 mm Hg mean of last two
of three measurements from two separate days and
receiving antihypertensive medications) in rural
communities in Bangladesh, Pakistan and Sri Lanka
Qualitative aims
A complementary qualitative study is planned in the
MCI arm with the following objectives: (1) to under-
stand facilitators and barriers to MCI from a stakeholder
perspective and (2) to seek the hypertensive individuals’
experience during the course of MCI strategy in relation
to components of the intervention, diagnosis of hyper-
tension, treatment, quality of life and sustainability of
intervention through in-depth interviews.
The central hypotheses of the study are as follows:
1. MCI will be more effective relative to usual care in
lowering the BP of adults with hypertension in rural
communities in Bangladesh, Pakistan and Sri Lanka.
2. MCI will be more cost-effective relative to usual care
when measured against common thresholds for
cost-effectiveness.
Trial design
The study is a stratified cluster randomized controlled trial
(RCT) in rural communities in three South Asian coun-
tries conducted according to the UK Medical Research
Council’s (MRC’s) framework for implementing complex
intervention trials [5]. A cohort of 850 individuals with
hypertension will be recruited in each country and
followed over a 2-year period in order to be able to
evaluate the BP change within individuals. Ethical
approval has been obtained from the Ethics Review
Committees of the International Centre for Diarrhoeal
Disease Research, Bangladesh (ICDDR, B) Aga Khan
University, the University of Kelaniya, the London
School of Hygiene & Tropical Medicine (LSHTM) and
Duke-NUS Singapore. A Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
checklist is provided as Additional file 1. The SPIRIT
deliverable items are shown in Fig. 1. The flow diagram
for the study protocol is included as Fig. 2.
Trial setting and randomization
The trial will be conducted in Bangladesh, Tangail District
(population 3.2 million) and Munshiganj District (popula-
tion 1.4 million); Pakistan, Thatta District (population 1.5
million); and Sri Lanka, Puttalam District (population 1.6
million). The unit of randomization will be a cluster defined
by 250–300 households as defined by local administration
according to CHW catchment area (each served by one to
two CHWs). These clusters are grouped in geographically
contiguous administrative units (AUs) as defined by the
local governments (12 sub-districts in Tangail, 6 sub-
districts in Munshignaj, 30 union councils in Thatta, 12
medical officers of the health division in Puttalam District)
such that each unit is served by one government clinic.
First, in the selected district of each country, 10 administra-
tive units will be deliberately sampled, and the respective
government clinic will be determined. Within each AU in
each country, an eligible cluster will be identified (one clus-
ter is defined as a village for Bangladesh, two to five neigh-
bouring villages for Pakistan and two Grama Niladhari
(GN) divisions for Sri Lanka). Each country will measure
the distance of clusters from the respective government
clinic measured by a GPS device. In each AU, clusters will
be stratified by their distance to respective government
clinic into two strata: FAR and NEAR (a distance of 2 km
or less will be defined as NEAR and more than 2 km as
FAR). In each arm (usual care or MCI), five AUs will be fur-
ther randomized into three NEAR and two FAR.
One NEAR cluster from each NEAR AU and one
FAR cluster from each FAR AU will be randomly se-
lected for subject recruitment. A minimum distance of
10 km between randomized clusters will be ensured.
Randomization will be stratified by country as well as
by the distance from the government clinic, and AUs
will be randomized in a 1:1 ratio to either MCI or usual
care within the six strata defined by the combination of
country and distance (NEAR versus FAR) using a
computer-generated randomization program at Singapore
Clinical Research Institute, Singapore.
Eligibility and recruitment
Inclusion criteria include individuals who:
1) Are of age ≥40 years
2) Reside in the selected clusters
3) Have hypertension defined either as:
(a)Persistently elevated BP (SBP ≥140 mm Hg or
DBP ≥90 mm Hg) from each set of last two of
three readings from two separate days, where BP
measurements on the same day were measured at
least 3 min apart
(b)Are maintained on antihypertensive medications
4) Are willing to give informed consent
Exclusion criteria include:
1. Permanently bedridden individuals too ill to
commute to the clinic
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2. Pregnant women or individuals with advanced
medical disease (those on dialysis, with liver failure
or with other systemic diseases)
3. Individuals who are mentally compromised and
unable to give informed consent
Intervention
The MCI will be rolled out in the 15 clusters assigned to
the intervention in the three countries (five in each).
Components of the MCI include:
1. Home health education (HHE) by government
CHWs: The standardized curricula have been
adapted to local diets and languages in the three
countries during the pilot feasibility study [5].
Training for CHWs in conveying HHE using a
structured behaviour change communication
approach will be carried out by a qualified
nutritionist for 3.5 h/day over 5 days (see details in
Additional file 2). During this time the CHWs will
also be trained in completing a paper-based HHE
checklist developed as part of the MCI (Additional
file 3). The health messages include information
on the deleterious effects of hypertension,
non-pharmacological interventions for preventing
and controlling hypertension and CVD, along with
advice on weight loss strategies, physical activity,
smoking cessation, avoiding excessive alcohol,
low salt and saturated fat intake, and high fruit
and vegetable intake.
The trained CHWs will go door to door and
deliver the sessions every 3 months in each cluster
(about 60 households with hypertension) per
CHW — a caseload consistent with the existing
services. CHWs will deliver HHE to all individuals
with elevated BP (SBP ≥140 mm Hg or DBP ≥
90 mm Hg) at any visit. The first HHE session is
expected to run for one hour with the second
session expected to last 30 minutes. Family members
(including those without hypertension) are also
invited to sit in the sessions. The HHE Checklist
Fig. 1 SPIRIT figure
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will be completed by the CHW at the end of the
session and submitted to the Local Health Office
(LHO) via the community health supervisor.
2. BP monitoring, and stepped-up referral to trained GP
using checklist: Every government CHW in the 15
intervention clusters will have a digital portable BP
device (Omron HEM-7300™ Blood Pressure
Monitor) and will be rigorously trained in
standardized methods for BP measurement.
CHWs will monitor the BP of all individuals
aged 40 years or older with hypertension
(as defined at baseline) at 3-monthly intervals
and will complete the CHW BP monitoring and
HHE checklist at each visit (Additional file 3)
including list of HHE sessions delivered. All
individuals with poorly controlled BP
(SBP ≥160 mm Hg or DBP ≥100 mm Hg) at
any visit will be referred to a trained GP.
The CHW will complete and submit the GP
management checklist (Additional file 4) to the
CHW supervisor to track the referrals.
3. Training providers in BP monitoring, management of
hypertension and using checklist: As in the
feasibility study, GPs and midlevel providers
(nurses, pharmacists) in public and private clinics
will be invited for training. All providers will be
trained in standardized BP measurement. In
addition, GPs will be trained in management of
hypertension. The Hypertension Management
Manual for Clinic Providers has been developed
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during the pilot feasibility study and includes
training on (1) measurement of BP, (2) provision of
lifestyle advice, (3) prescription of antihypertensive
therapy and (4) risk stratification for lipid lowering.
Those individuals with any of the following will be
classified as being at ‘high risk for CVD’: (a) aged
55 years older with SBP ≥160 mm Hg (b) past
history of diabetes, (c) past history of heart disease,
(d) past history of stroke or (e) current smokers;
these individuals will be initiated on statins.
The GPs will also be trained in completing a GP
referral checklist (Additional file 5). A pre- and post-
test of knowledge and practices will be administered.
As in the feasibility study, we anticipate at least 66%
of all GPs in the intervention clusters to be trained.
4. Designating hypertension triage counter and
hypertension care coordinator at the government
clinics: A functional hypertension triage counter
will be established at the government health clinic
enrolled in the study. This triage counter will
facilitate care of hypertensive individuals who
present to the clinic with a GP referral checklist.
The counter will be equipped with a digital BP
device for standardized measurement of BP by a
trained clinic nurse/assistant before evaluation by a
trained physician. Additionally, a hypertension care
coordinator will be appointed at each government
clinic to facilitate tracking of referrals by the CHW
of individuals with poorly controlled BP.
5. Compensation for additional health services and
targeted subsidies: The government CHWs will
receive a pre-decided compensation of up to 0.2
FTE equivalent upon submission of the CHW BP
monitoring and HHE checklist. Hypertensive
individuals who are deemed poor (according to local
policy in each country developed by the study team)
with poorly controlled BP (SBP ≥160 or DBP
≥100 mm Hg) will receive a travel voucher for a
clinic visit, and a free supply of antihypertensive
medications will be provided. However, each country
will have the flexibility to conform the subsidies to
fit within the existing models of disbursements used
in their respective systems, ensuring appropriate
vetting for means testing, logistics and accountability
of disbursement policy and procedures.
Treatment algorithm
A standardized protocol has been developed and re-
fined by study nephrologists, cardiologists, internists
and family physicians using non-pharmacologic and
pharmacologic interventions following National Institute
for Health and Care Excellence (NICE) guidelines [7].
The antihypertensive agents include calcium channel
blockers (CCBs), angiotensin-converting-enzyme (ACE)
inhibitors (ACEIs) or angiotensin receptor blockers
(ARBs) and thiazide-like diuretics. The target BP will
be SBP <140 mm Hg and DBP <90 mm Hg for all par-
ticipants. Individuals with hypertension classified as be-
ing at ‘high risk for CVD’ based on the risk
stratification will be treated with statins. Details are
provided in the Antihypertensive Medication Treat-
ment Algorithm (Additional file 6). As in the pilot
feasibility study, prescription of inexpensive, generic
antihypertensive medicines and statins has been
encouraged.
Usual care
Usual care will comprise existing services in the commu-
nity without any additional training. Services include
government health worker home visits for preventive
maternal and child health and family planning services.
However, these do not include formal screening or
monitoring of BP or lifestyle advice for the prevention of
hypertension. The existing clinic GPs in the communi-
ties (public and private) cater to 50–70 hypertensive
individuals/day with an average contact time of 5–
10 min per individual (per the pilot feasibility study)
[5]. Whereas these providers are accustomed to pro-
viding care for common childhood illnesses and infec-
tious diseases (diarrhoea, fever, malaria) that have
traditionally burdened developing countries, the systems
are not well organized for treatment of non-communicable
diseases (NCDs), including hypertension.
Thus, usual care services do not include formal
screening or monitoring BP or lifestyle advice for either
prevention or management of hypertension; however,
these services are included in the multicomponent inter-
vention (MCI) arm.
Screening and baseline data collection
The research staff masked to randomization status will
first obtain a list of all members living in the households
in the selected clusters from the Local Health Office and
will visit all adults aged 40 years and older. Informed
consent will be obtained for participation in the study.
Those who consent will be screened for eligibility into
the study. Standardized BP will be measured three
times by research staff with a calibrated automated de-
vice, the Omron HEM-7300™ Blood Pressure Monitor,
with the individual in a sitting position [8–10]. Readings
will be taken 3 min apart. Individuals with elevated BP
(SBP ≥140 mm Hg or DBP ≥90 mm Hg) of the last two of
three readings on the first visit will be visited again after
2 weeks for re-measurement of BP to confirm hyperten-
sion (the BP measurements as described above will be
repeated f), while those already on antihypertensive medi-
cations will be recruited at the first visit.
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An interviewer-administered questionnaire translated
into the local languages (Bangla, Urdu, Sindhi, Sinhala
and Tamil) will be presented. Domains include socio-
demographics, diet, lifestyle and behaviour, co-morbidities
and health-related quality of life (EQ-5D-5L), health-
seeking behaviours and associated costs. Adherence to
antihypertensives and statins will be assessed by admin-
istering the Morisky scale [11]. Adiposity measures will
be recorded. Fasting blood samples will be collected for
plasma glucose, serum creatinine and lipids, and a
morning spot urine sample for sodium, albumin and
creatinine [12, 13].
In each of the 30 clusters, participants on antihyperten-
sive medications with uncontrolled hypertension (defined
as persistently elevated SBP >140 mm Hg or DBP
>90 mm Hg from each set of two readings from 2 separate
days) will be offered informed consent to undergo 24-h
ambulatory BP monitoring (ABPM) with the Ultralight
90207™ model. Subjects meeting the eligibility criteria will
be recruited consecutively (14 per cluster).
The MCI will be rolled out in the 15 clusters assigned
to the intervention in three countries (five clusters in
each). The CHW will then visit the household for HHE
and will refer the individuals using the assigned GP re-
ferral checklist. The MCI team (including trainers and
oversight personnel) and data collectors will be separate
teams in each country. Although maintaining blinding at
an operational level is challenging given the pragmatic
nature of the MCI, measures will be taken to maintain
masking of data collectors to randomization status by
avoiding overlapping responsibilities of research data
collectors and service delivery teams in the health care
sector.
Outcome measurements
Outcome assessors masked to randomization status will
pay 6-monthly home visits for a total of 2 years. BP will be
measured with the calibrated automated device Omron
HEM-7300™ Blood Pressure Monitor (as in the baseline)
with the hypertensive individual in the sitting position.
Readings will be taken 3 min apart. The average of the last
two of three readings will be considered in the analysis.
Information on behavioural risk factors (diet, physical
activity, tobacco use and adiposity measures) will be
obtained via an interviewer-administered questionnaire.
Individuals will be asked to keep a record of the number
of visits to the providers, type of facility (public or pri-
vate), transportation costs, receipts of purchase of drugs
and hospital visits. Based on our previous experience in
urban Pakistan and the feasibility study in rural commu-
nities, the subjects are likely to maintain the records
when requested in advance. Moreover, local information
on market rates will be collected to supplement any
missing information [5, 14]. Information on serious
adverse events including death, hospitalization and any
other serious events will be recorded.
The 24-h ABPM will be repeated at year 1 and at the
final visit at year 2 post-randomization on the cohort en-
rolled in the ancillary study.
Primary effectiveness measure
The primary effectiveness measure is change in SBP
from baseline to final follow-up at 2 years post-
randomization. Both measurements will be taken by
independent data collectors who will be masked to
randomization.
Secondary effectiveness measures
The secondary effectiveness measures are as follows: (1)
BP controlled to target (SBP <140 mm Hg and DBP
<90 mm Hg; (2) composite outcome of death (all cause)
or hospital admission due to coronary heart disease
(CHD), heart failure or stroke; (3) incremental cost per
quality-adjusted life year (QALY) gained from baseline
to end of follow-up [15–17]; (4) change in antihyperten-
sive medication adherence; (5) change in BMI; (6)
change in dietary salt intake (urinary excretion); (7)
change in prevalence of current smokers; (8) incident
diabetes; (9) change in serum lipid levels; (10) change in
INTERHEART CVD risk score; (11) incidence of ad-
verse outcomes (medication side effects, sick days absen-
teeism, low QALY between randomized groups); (12)
change in estimated glomerular filtration rate (eGFR);
(13) change in urine albumin excretion.
Primary cost-effectiveness measures
The primary cost-effectiveness measures are incremental
cost per mm Hg BP reduction from baseline to end of
follow-up at 2 years post-randomization and incremental
cost per projected CVD disability-adjusted life year
(DALY) averted [14, 18].
Secondary cost-effectiveness measure
The secondary cost-effectiveness measure is incremen-
tal cost per QALY gained from baseline to end of
follow-up [15–17].
Ancillary study outcome
The primary outcome for this sub-study is change in 24-
h ambulatory mean SBP from baseline to final follow-
up. The secondary outcome is 24-h ambulatory mean
DBP.
Process measures Fidelity and quality of implementa-
tion will be assessed, and explanations for potential dis-
crepancies in observed and expected outcomes will be
sought, which will aid future scale-up. As in the pilot
study [5], these measures will include:
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1. Proportion of planned HHE sessions delivered at the
household level (HHE session checklist collected
from CHW)
2. Proportion of individuals with hypertension referred
by CHW to trained physician (physician referral
checklist collected from hypertensive individuals)
3. Proportion of individuals with hypertension
evaluated by trained physician (physician
management checklists collected from the district
health office)
In addition, deviations from the MCI protocol and also
participant and health care provider perceptions of the
quality and implementation of the intervention will be
obtained.
Statistical analysis
All main analyses will be based on the intention-to-treat
population so that individuals will be analysed in the
arm to which they were randomized, even if they did not
adhere to the randomization (e.g. if an individual in the
MCI arm did not participate in the MCI intervention).
The chief principal investigator (PI) and site PIs will be
masked to randomization status of all analytic data. The
primary outcome is SBP change from baseline to 2 years.
The four 6-monthly changes from baseline measure-
ments (at 6, 12, 18 and 24 months) for all subjects will
be modelled simultaneously using a likelihood-based
generalized linear mixed model for repeated measures
(MMRM) approach. This approach is a subject-level ana-
lysis that incorporates a cluster random effect. Although a
Gaussian distribution with identity link function is pre-
specified for the primary outcome, appropriate distribu-
tions within the exponential family and corresponding link
functions will be employed in the case of non-normality.
An unstructured matrix will be used to model the within-
subject variance-covariance structure. If this model fails to
converge, other variance-covariance structures will be
considered. Primary analyses models will include fixed ef-
fects for baseline SBP, country, indicator for distance from
clinic (FAR or NEAR), age, gender, intervention arm, visit
number and the intervention arm-by-visit number inter-
action. The primary outcome of interest at 2 years post-
randomization will be estimated with corresponding 95%
confidence interval using the appropriate contrast at the
final visit. Additional analyses will include interactions for
country and treatment group to determine whether the ef-
fects differ by country. If the interaction effect is found to
be clinically meaningful, an MMRM model similar to the
primary analysis model will be performed separately for
each country. Other analyses (sensitivity, secondary and
subgroup analyses) will be explained in a detailed statis-
tical analysis plan paper.
Sample size
The planned sample is 2550 subjects with hypertension,
involving 3 strata (countries), with an equal number of
clusters per strata (10 clusters per country or 30 clusters
total) and similar cluster sizes (85 hypertensive subjects
per cluster). Based on findings observed in a previous
study in urban Pakistan, and assuming a conservative
intraclass correlation coefficient (ICC) of 0.02, 80%
follow-up within clusters at 2 years post-randomization
(68 hypertensive subjects per cluster) and a two-sided
type I error rate of 5%, the trial will provide >99% power
for the overall test to detect a difference between arms in
SBP reduction as small as 4 (SD 11) mm Hg [4, 14, 18].
The study will use 5 mm Hg as the clinically meaningful
difference between the two arms for reduction in SBP.
If heterogeneity in intervention effect across countries
is evident (e.g. a reduction in SBP of 3 (SD 11) mm Hg
in one country and 9 (SD 16) mm Hg in the other two
countries), the trial has 80% power to detect such differ-
ences in intervention effects based on the following as-
sumptions: ICC of 0.02 and type I error rate of 1.6%
(based on a Bonferroni adjustment), 30 clusters and 85
participants per cluster. In addition to this, the trial has
>80% power to detect a difference of 4 mm Hg (SD 11)
in SBP reduction between the MCI and usual care arms
for each country separately, for an ICC of 0.02, a type I
error rate of 5% and 10 clusters of size 85 subjects per
country. Furthermore, the high power also ensures that
the main effect is adequately powered even after adjusting
for dropouts, at both the participant and cluster levels.
Therefore, the study is not over-powered for heterogeneity
or dropouts (missing data). Power and Sample Size (PASS)
software was used for the power calculations. Based on
our previous work in urban Pakistan, and expecting a
somewhat lower attrition rate in rural areas, the attrition
rate is likely to be less than 15% at the end of 2 years in
the overall study; therefore, our assumptions about
follow-up rates are conservative [4].
Data monitoring
The chief PI (THJ) will be responsible for the overall
management of the trial. The day-to-day management at
each site will be the responsibility of the site PIs (AN, IJ,
AdS). The study management group will comprise the
chief PI, statisticians (MG and PA) and validation statis-
tician (ELT), health economists (EAF and MB), qualita-
tive expert (HLQ), site PIs and co-PIs, data managers,
project coordinators and research assistants. The Trial
Steering Committee (TSC) comprises an independent
chair (a senior professor of cardiovascular disease) plus
independent experts in statistics, qualitative and mixed-
methods research, chronic disease advocacy and health
policy and finance. An independent Data Safety and
Monitoring Board (DSMB) has been established as per
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MRC guidelines to review quality and safety issues. The
TSC and DSMB operate in line with the MRC terms of
reference as amended and agreed on by members at
their first meeting.
Qualitative study: facilitators and barriers to
multicomponent public health intervention
Conceptual framework
The aim of this study is to identify patient and health
care provider experience relating to hypertension aware-
ness, treatment and management; this study will be
guided by the behaviour change theoretical framework.
This framework draws on theories from implementation
research [19] and behaviour change [20]. It encapsulates
the barriers to hypertension control and makes it pos-
sible to explore mediating pathways and moderators
[21]. We will explore sub-themes for investigating the
implementation of evidence-based practice, organized
under three main themes whereby a change in behaviour
requires a strong commitment for change (intention bar-
riers), the necessary skills and abilities to perform the
behaviour (capability barriers), with no health system
constraints, as well as barriers that are external to pa-
tients’ or health care providers’ control (health care sys-
tem barriers) [22].
The second stage of this study will involve conducting
semi-structured interviews with hypertensive individuals,
CHWs, health care professionals, providers and policy
makers. These interviews will be conducted annually at
three time points: prior to the intervention, after 1 year
of intervention and after the study completion. The
study will adopt a thematic analysis of semi-structured
interviews using an adaptation of a behaviour change
theoretical framework and a health system’s assessment
framework, adopting some techniques of grounded theory
such as line-by-line analysis, identifying deviant cases and
using the constant comparison method (Table 1).
The interviews will be audio recorded and translated
directly from the respective languages to English on tran-
scripts by an expert bilingual, native speaker. Deductive
and inductive data analyses will be used. Relevant quotes
representative of the analysis will be incorporated into the
publications. Data will be managed and analysed using
QSR International’s NVivo 10™ software.
Economic evaluation
Both a budgetary impact analysis and a cost-effectiveness
analysis will be performed, the latter using the intention-
to-treat principle. The budgetary impact analysis will track
the total and per participant costs (including travel time
costs monetized at local wage rates) of program delivery
using an activity-based costing (ABC) approach. Using
this approach, all relevant labor, materials and supplies,
contracted services, travel vouchers and opportunity costs
required to deliver the interventions will be captured by
key activities. This information will not only feed into the
cost-effectiveness analysis, but it will also allow policy
makers within each country to identify the full and public
sector costs of the program, should it be expanded beyond
the trial communities.
The incremental cost-effectiveness evaluation will
follow the approach we have employed in prior studies
[23] and focus on the additional cost per unit reduction
in CVD DALYs relative to standard care. The DALY is a
generic measure of the burden of disease that combines
healthy life years lost because of premature mortality
with those lost due to disability. The metric thus enables
assessment of burden of disease and the extent of bur-
den that can be removed due to successful interven-
tions. Using this approach will allow for comparing our
results with other programs aimed at improving health
outcomes and against common thresholds for cost-
effectiveness, such as WHO-CHOICE recommenda-
tions [24].
CVD DALYs averted will be computed using the ap-
proach presented in Jafar et al., which assumes a linear
relationship between blood pressure and DALYs such
that a 1 mm Hg reduction in BP leads to a 2.2% reduc-
tion in CVD DALYs [14, 18].
In addition, we will quantify incremental costs per
QALY gained over the 2-year time period based on the
EQ-5D-5L scores. This analysis assumes that there may
be benefits to participants irrespective of changes in
blood pressure.
All analyses will be conducted from a societal per-
spective (including payer and participant costs and
benefits) and separately from a third party payer’s
perspective, as results from the latter may be most
relevant to potential government payers. Results will
be estimated for the three countries together for wider
generalizability to South Asia and other low and/or
middle income countries (LMICs), and for each coun-
try separately for local applicability, and will be com-
pared to established benchmarks for cost-effectiveness
[25]. One-way and n-way sensitivity analyses and
cost-effectiveness acceptability curves that graphically
Table 1 Number of participants per country over a 2-year
period
Time points
Participants
Prior to
intervention
After 1 year of
the intervention
After 2 years of
the intervention
Hypertensive patients 20 20 20
Health care
professionals
15 – 15
Policy makers 7–10 – 7–10
Total 42–45 20 42–45
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present the probability that the MCI is cost-effective
for a range of willingness-to-pay metrics that a deci-
sion maker may consider will also be presented. Based
on the results, we will discuss the extent to which the
MCI is likely to be cost-effective in rural communities
in other LMICs.
Discussion
High BP is the leading attributable risk factor for disability
and mortality from CVD globally, and it accounts for a
third of age-standardized deaths in South Asia [26]. The
early age of onset of CVD in South Asians worsens the
consequences through a reduction in productive life years.
About one in four adults suffers from hypertension in
Bangladesh, Pakistan and Sri Lanka [27–29]. Evidence on
effective health systems strategies to manage hypertension
is limited, especially in rural South Asia where case fatality
rates from CVD are even higher [30].
In the COBRA-BPS study, we will evaluate the effect-
iveness and cost-effectiveness of a comprehensive ‘multi-
component intervention (MCI)’ for effective delivery of
hypertension care using the rural predominantly public
primary care infrastructure. The MCI approach has been
modified from a two-component strategy of HHE and
training of GPs, previously shown to be successful in an
urban private practice setting, into a five-component
MCI with the additional components essential for moni-
toring of individuals with poorly controlled hypertension
and sustainable care delivery via subsidies for travel to
clinic and antihypertensive medications through the
public health care infrastructure.
The MCI is also expected to strengthen the capacity of
the health system by establishing a team-based approach
and referral links with documentation of standardized care
to enhance hypertension management. The trial uses
hypertension as an entry point into developing rural NCD
health services, and the HHE component of our interven-
tion is the first-line approach for management of diabetes
and other common NCDs. The use of statins among
individuals at high risk for CVD follows an up-to-date
comprehensive CVD risk reduction strategy. Models of co-
ordinated care are recommended by the World Health
Organization (WHO) for communicable disease programs,
such as directly observed treatment (DOT) for tubercu-
losis, HIV and management of malaria [31]. Our trial will
provide direct evidence of the value of using comparable
models and platforms for NCD management. Furthermore,
the training components in the intervention leverage the
existing infrastructure and will create economies of scale
during roll out at national and regional levels if the trial is
successful. NCDs have recently been featured on the na-
tional health policy agenda in Bangladesh, Pakistan and Sri
Lanka. Contrasting the experiences from these three coun-
tries should provide valuable lessons to implement an
action plan and also validate the usefulness of our ap-
proach for other countries in the region and beyond.
Trial status
Participants are currently being recruited. The first pa-
tient was enrolled in April 2016. The study SPIRIT time-
line details are shown in Fig. 1.
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